✦ The floor
Discussion
Signed responses from readers of the wire.
✦ Clinical Takeaway ✦
No actionable change — this is a commentary letter raising a methodological concern about rimegepant trial interpretation; audiologists managing vestibular migraine should await further clarifying evidence.
✦ Why It Matters ✦
Vestibular migraine is a common cause of episodic vertigo seen in audiology and neurotology clinics, and clarifying how treatment timing vs. baseline severity affects outcomes has real implications for clinical decision-making.
✦ Key Points ✦
- 01Letter published in Cephalalgia challenging interpretation of rimegepant data for vestibular migraine.
- 02Argues that baseline symptom severity is a distinct variable from treatment timing.
- 03Rimegepant is a CGRP receptor antagonist used acutely for migraine.
- 04Vestibular migraine causes episodes of dizziness/vertigo alongside headache.
- 05No new primary data presented; methodological critique only.
✦ Claims & Evidence ✦
ClaimEvidenceSupport
Baseline severity and treatment timing are distinct variables that should not be conflated in rimegepant trial analyses.
opinionunclear✦ Research metadata ✦
- PMID
- 42615616
- DOI
- 10.1177/03331024261474832.
- Journal
- Cephalalgia
- Publication type
- editorial
- Evidence level
- 5
- Population
- Adults with vestibular migraine treated acutely with rimegepant
- Intervention
- Rimegepant (acute treatment for vestibular migraine)
Primary outcomes
Relationship between baseline severity and treatment timing on outcomes